Intrexon T1D Partners Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Joint Venture
  • Financing Rounds
  • 1

Intrexon T1D Partners General Information

Description

Developer of a therapy for the treatment of Type 1 diabetes. The company is focused on development of an antigen-specific immunotherapy both for early-stage patients before they become insulin dependent, and in certain advanced-stage patients for the potential prevention of the requirement for external administration of insulin.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 20374 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intrexon T1D Partners Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Intrexon T1D Partners‘s full profile, request access.

Request a free trial

Intrexon T1D Partners Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Intrexon T1D Partners‘s full profile, request access.

Request a free trial